You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The bill, which was overwhelming passed by both the Senate and the House, would boost the National Institutes of Health's budget by $1.25 billion.
The firm will scale US-based testing capacity for its LiquidHallmark liquid biopsy assay, which uses amplicon-based technology to detect cancer-related mutations.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The companies will work with labs to improve payors' understanding of the costs of performing PD-L1 testing and the value it provides to patient care.
The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.
Novitas added multiple leukemia biomarkers to its coverage determination, as well as the ThyGeNEXT molecular panel.
The tests are covered when the patient has a personal history of melanoma and the test has demonstrated clinical and analytical validity.
The test assesses multiple factors, including single-/multi-nucleotide variants, short insertions and deletions, and microsatellite instability status.
Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.